Peptide Therapy for Men: GLP-1, Sermorelin, and NAD+ in Male Physiology

Peptide therapy is not inherently gendered, but male physiology does create a distinct clinical context for GLP-1 receptor agonist therapy, sermorelin, and NAD+ protocols. Body composition starting points differ. The endocrine interactions are different. The goal framing is often different. And a clinical program designed for one patient population will not automatically translate to another.

This article covers how the three most common telehealth peptide protocol categories — GLP-1 receptor agonists, sermorelin, and NAD+ — apply in male physiology. It is not a marketing piece about outcomes. It is an explanation of the clinical logic, the physiologic mechanisms that are sex-relevant, and what male patients should understand before starting a prescriber evaluation.

GLP-1 receptor agonist therapy in men

Body composition starting point

Men typically carry a higher proportion of visceral adipose tissue (VAT) relative to subcutaneous adipose tissue than women at equivalent BMI. Visceral adiposity is metabolically active in ways that carry greater cardiometabolic risk: it drives insulin resistance, contributes to non-alcoholic fatty liver disease, and produces inflammatory cytokines at higher rates than subcutaneous fat.

GLP-1 receptor agonist therapy has been shown in clinical trials to reduce both VAT and subcutaneous fat, with some data suggesting proportionally greater reductions in visceral fat. For male patients whose metabolic risk is primarily VAT-driven, this mechanism is clinically relevant beyond what scale weight alone captures.

The testosterone connection

Male patients often ask whether GLP-1 therapy affects testosterone. The answer requires understanding the mechanism.

Adipose tissue expresses aromatase — the enzyme that converts androgens (including testosterone) to estrogen. Men with elevated body fat, particularly visceral fat, often have elevated aromatase activity, which accelerates testosterone-to-estrogen conversion. The result is a lower free testosterone level, elevated estradiol, and the downstream effects of that hormonal ratio: reduced libido, reduced lean mass anabolism, fatigue, mood changes.

GLP-1 therapy is not a testosterone treatment. It does not directly stimulate testosterone production or inhibit aromatase. But fat mass reduction — which GLP-1 therapy produces — reduces the adipose tissue volume that carries aromatase activity. For men whose low testosterone is functionally secondary to excess adiposity and elevated aromatase, fat loss can produce an improvement in the testosterone/estradiol ratio that the patient experiences as meaningful.

This is not a guaranteed outcome and it is not a reason to prescribe GLP-1 therapy as a testosterone optimization strategy. It is a downstream physiologic relationship that a prescriber will factor into the clinical picture when relevant.

Muscle mass preservation

Male patients are typically more concerned than female patients about lean mass loss during a caloric-deficit weight loss program. This concern is clinically grounded — aggressive caloric restriction, particularly without adequate protein intake, does reduce lean mass.

GLP-1 receptor agonist therapy reduces caloric intake through appetite suppression, which creates a caloric deficit. If protein intake is inadequate and resistance training is absent, lean mass loss can occur alongside fat mass loss.

The clinical approach to preserving lean mass during GLP-1 therapy in male patients generally includes:

• Protein adequacy. Prescribers typically recommend protein intake at or above the lean-mass maintenance threshold (commonly cited at 1.6 to 2.2 grams per kilogram of body weight per day) while on a caloric-deficit protocol.
• Resistance training. Resistance exercise is the primary stimulus for lean mass preservation during a caloric deficit. Patients who incorporate resistance training during GLP-1 therapy consistently show better lean mass outcomes than patients who do not.
• Titration pacing. Aggressive dose escalation that produces very rapid weight loss also tends to produce more lean mass loss than gradual titration that allows the body to adapt.

Male patients with a specific body recomposition goal — reduced fat mass alongside maintained or increased lean mass — should communicate that goal clearly during their clinical intake so the prescribing clinician can frame the protocol appropriately.

Microdose protocols for non-obese male patients

A subset of male patients pursuing GLP-1 therapy are not clinically obese but want to use the medication for metabolic and body composition optimization — typically visceral fat reduction, appetite regulation, or metabolic marker improvement. This is the "microdosing" framing covered in more detail in the microdose GLP-1 protocol articles on this site.

Microdose protocols in non-obese male patients represent an off-label clinical application that requires a thorough prescriber evaluation. The evidence base is less developed than for weight-loss indications. The prescriber's evaluation determines appropriateness on an individual basis, not population-level criteria.

Sermorelin in men

What sermorelin does

Sermorelin is a growth-hormone-releasing hormone (GHRH) analog — a synthetic version of the first 29 amino acids of endogenous GHRH. It binds to pituitary GHRH receptors and stimulates pulsatile growth hormone secretion through the body's own feedback axis, rather than delivering exogenous GH directly.

The distinction matters. Exogenous GH delivery bypasses the body's feedback regulation. Sermorelin-stimulated GH release operates within the feedback axis — it can be suppressed by somatostatin when GH levels are sufficient, which limits the risk of supraphysiologic GH levels.

The clinical application at TelePeptide is specifically within the endocrine-axis framing: sermorelin is prescribed under endocrine evaluation for patients with documented age-related decline in GHRH-axis activity, not as a performance enhancement tool applied indiscriminately.

Why it is prescribed for men

The primary clinical goals male patients pursue through sermorelin prescribing are:

Body composition. Growth hormone participates in lipolysis (fat mobilization) and in signaling pathways that support lean mass. Patients with documented GHRH-axis decline may see improvements in body composition — specifically reduced fat mass and preserved or improved lean mass — when GHRH-axis function is supported.

Recovery quality. Growth hormone is primarily released during slow-wave sleep. Patients with GHRH-axis decline often report impaired sleep quality and recovery from physical exertion. Sermorelin's pulsatile stimulation of nocturnal GH release is associated in patient experience with improved sleep quality and perceived recovery.

Metabolic function. GH participates in glucose metabolism and insulin sensitivity. The relationship is complex — high GH can impair insulin sensitivity, while physiologically appropriate GH in the context of age-related decline may have the opposite effect. The prescriber evaluates the individual patient's metabolic picture.

What sermorelin does not do

Sermorelin does not replace testosterone. It does not operate through the hypothalamic-pituitary-gonadal (HPG) axis. Male patients sometimes conflate GH-axis support with testosterone optimization because both are associated with body composition and recovery outcomes. They are biologically separate systems with separate prescribing pathways.

Male patients who have testosterone-specific concerns (low free testosterone, symptomatic hypogonadism, elevated SHBG) need a separate clinical evaluation focused on the HPG axis. TelePeptide prescribers will evaluate what is within scope and refer to appropriate specialists as needed.

For more detail on sermorelin dosing, timing, and what the first three months typically look like, see the sermorelin dosing and timing article.

NAD+ protocols in men

The cellular context

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every cell, central to the electron transport chain (ATP production), DNA repair through PARP enzymes, and sirtuin-mediated gene expression regulation. Intracellular NAD+ levels decline with age and with metabolic stress.

Male patients pursuing NAD+ therapy typically frame the goal as energy and cognitive performance, recovery from training, or longevity-oriented cellular support. These goals are addressed in the NAD+ cellular energy article and the NAD+ for performance article on this site.

Administration in male patients

NAD+ is administered subcutaneously in TelePeptide's home-injection protocol. The self-injection protocol is the same regardless of sex — the clinical distinction is in dosing, which the prescriber determines based on the patient's clinical goals, baseline status, and tolerance.

Male patients with higher lean mass and higher energy expenditure may be evaluated for higher-end dosing within the clinical range. The prescriber determines the appropriate dose and schedule based on the individual evaluation, not on a standard male-dose assumption.

Combined protocols

Some male patients are prescribed more than one protocol under separate clinical evaluations — for example, GLP-1 for metabolic management alongside sermorelin for GHRH-axis support. When multiple protocols are prescribed by the same prescribing group, the clinician has a complete picture of both prescriptions and can evaluate for interactions, timing considerations, and combined clinical goals.

TelePeptide discloses that clinical services are provided by MD Integrations, P.C. — a contracted medical group operating a multi-state network of licensed physicians, NPs, and PAs — with prescribing decisions made at the individual patient level.

Starting a clinical evaluation as a male patient

The intake process at TelePeptide begins with a comprehensive intake form that captures your clinical history, medication list, health goals, and relevant lab results if available. The prescribing clinician reviews the intake and determines which protocol, at what dose, is clinically appropriate — or whether the clinical picture requires more evaluation before a prescription is appropriate.

Male patients commonly report two intake errors worth flagging:

Understating health goals. Patients who are primarily interested in body recomposition but describe their goal as "weight loss" may receive a clinical framing that doesn't reflect their actual priorities. Be specific: if your goal is fat mass reduction with lean mass preservation, say so. If your goal is recovery and sleep quality, say so. The prescribing framing follows the documented clinical goal.

Omitting relevant medications. Several medications interact with the protocols described here. Testosterone therapy, thyroid medications, metformin, statins, and other cardiovascular medications are all clinically relevant to the prescribing evaluation. Complete medication disclosure is required for accurate prescribing.

For program options and current pricing, see the programs index and the cost breakdown article. TelePeptide serves 48 US states + DC (excludes AK and MS).

---

Compounded peptide preparations are not FDA-approved as finished drug products. Clinical services provided by MD Integrations, P.C. — a contracted medical group operating a multi-state network of licensed physicians, NPs, and PAs. Available in 48 US states + DC (excludes AK and MS). Not medical advice. Individual results vary. Consult your prescriber regarding your specific clinical situation.